@article{dd3c95ef7e3c450fa13ce7efd6cc8d88,
title = "Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol",
keywords = "Ad26.Cov2.S, BNT162.b2, COVID-19, Heterologous vaccine regimen, Homologous vaccination regimen, SARS-CoV-2, mRNA1273, randomized clinical trial",
author = "Sablerolles, {Roos S. G.} and Abraham Goorhuis and GeurtsvanKessel, {Corine H.} and {de Vries}, {Rory D.} and Huckriede, {Anke L. W.} and Koopmans, {Marion P. G.} and Melvin Lafeber and Postma, {Douwe F.} and {van Baarle}, Debbie and Visser, {Leo G.} and Dalm, {Virgil A. S. H.} and Kootstra, {Neeltje A.} and Rietdijk, {Wim J. R.} and {van der Kuy}, {P. Hugo M.}",
note = "Funding Information: The trial is funded by ZonMW in the COVID-19 program (project grantnumber: 10430072110001).",
year = "2021",
month = sep,
day = "24",
doi = "https://doi.org/10.3389/fimmu.2021.753319",
language = "English",
volume = "12",
journal = "Frontiers in immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",
}